Lannett Company commences marketing Aspirin and Extended-Release Dipyridamole Capsules.
M2 PHARMA-June 19, 2019-Lannett Company commences marketing Aspirin and Extended-Release Dipyridamole Capsules
(C)2019 M2 COMMUNICATIONS
Lannett Company Inc. (NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced on Tuesday that it has started marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, from Boehringer Ingelheim Pharmaceuticals Inc.
According to contract research organisation, IQVIA, total US sales of Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, amounted to around USD158m for the 12 months ended April 2019, although actual generic market values are likely to be lower.
Tim Crew, chief executive officer of Lannett, stated: "The launch of Aspirin and Extended-Release Dipyridamole Capsules, an internally developed product, represents a meaningful opportunity. We continue to make progress on a number of operational fronts. Since January of this year, we have improved our capital structure with open market purchases of approximately USD62 million of our Term loans, which is in addition to the approximately USD67 million of required annual loan amortisation, added drug development expertise to our board of directors and, including Aspirin and Extended-Release Dipyridamole, launched seven new products."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 19, 2019|
|Previous Article:||Alligator Bioscience applies for phase one clinical trial authorisation for ATOR-1017.|
|Next Article:||Frost & Sullivan honours Piramal Pharma Solutions.|